Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients

被引：0
|
作者：
Marit A. C. Vermunt
Merel van Nuland
Lisa T. van der Heijden
Hilde Rosing
Jos. H. Beijnen
Andries M. Bergman
机构：
[1] The Netherlands Cancer Institute,Department of Pharmacy and Pharmacology
[2] The Netherlands Cancer Institute,Department of Medical Oncology
[3] Utrecht University,Department of Pharmaceutical Sciences
[4] Modra Pharmaceuticals B.V.,Department of Oncogenomics
[5] The Netherlands Cancer Institute,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2022年 / 89卷
关键词：
Docetaxel; Pharmacokinetics; Metastatic castration-resistant prostate cancer; Metastatic hormone-sensitive prostate cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：785 / 793
页数：8
相关论文
共 50 条
  • [1] Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
    Vermunt, Marit A. C.
    van Nuland, Merel
    van der Heijden, Lisa T.
    Rosing, Hilde
    Beijnen, Jos H.
    Bergman, Andries M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (06) : 785 - 793
  • [2] Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
    Michael T. Schweizer
    Roman Gulati
    Elahe A. Mostaghel
    Peter S. Nelson
    R. Bruce Montgomery
    Evan Y. Yu
    Heather H. Cheng
    Medical Oncology, 2016, 33
  • [3] Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
    Schweizer, Michael T.
    Gulati, Roman
    Mostaghel, Elahe A.
    Nelson, Peter S.
    Montgomery, R. Bruce
    Yu, Evan Y.
    Cheng, Heather H.
    MEDICAL ONCOLOGY, 2016, 33 (07)
  • [4] Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer
    Mager, Rene
    Savko, Olga
    Boehm, Katharina
    Thomas, Anita
    Dotzauer, Robert
    Borgmann, Hendrik
    Jaeger, Wolfgang
    Thomas, Christian
    Haferkamp, Axel
    Hoefner, Thomas
    Tsaur, Igor
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (12) : 999 - 1005
  • [5] Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer
    Wang, Zhipeng
    Liu, Haoyang
    Zhu, Qiyu
    Chen, Junru
    Zhao, Jinge
    Zeng, Hao
    BMC CANCER, 2024, 24 (01)
  • [6] Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancer
    Gschwend, Juergen E
    Miller, Kurt
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (01): : 41 - 49
  • [7] Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
    Eymard, Jean-Christophe
    Oudard, Stephane
    Gravis, Gwenaelle
    Ferrero, Jean-Marc
    Theodore, Christine
    Joly, Florence
    Priou, Frank
    Krakowski, Ivan
    Zannetti, Alain
    Thill, Laurence
    Beuzeboc, Philippe
    BJU INTERNATIONAL, 2010, 106 (07) : 974 - 978
  • [8] Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
    Kreis, Kristine
    Horenkamp-Sonntag, Dirk
    Schneider, Udo
    Zeidler, Jan
    Glaeske, Gerd
    Weissbach, Lothar
    BJU INTERNATIONAL, 2022, 129 (04) : 470 - 479
  • [9] Management of metastatic castration-resistant prostate cancer following docetaxel
    Beuzeboc, Philippe
    Ropert, Stanislas
    Goldwasser, Francois
    Zerbib, Marc
    BULLETIN DU CANCER, 2012, 99 : S66 - S72
  • [10] Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients
    Poon, Darren M. C.
    Chan, Kuen
    Chan, Tim-Wai
    Ng, Bryan
    Siu, Steven
    Ng, Joyce
    Johnson, David
    Lee, Ka Chai
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 39 - 47
12345